🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to researchers.

An International Health Concern

The sexually transmitted infection are escalating globally, with data suggesting more than 82 million instances per year. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Gain Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP worked alongside the drug firm its industry partner to develop it.

“This approval signifies a significant shift in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Global Access

As per results detailed in a prominent scientific publication, the new drug successfully treated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which combines a dual-drug approach. The trial enrolled hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have shared optimism. The availability of a easy-to-administer therapy like this is described as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the disease for individuals and to prevent the spread of untreatable gonorrhoea around the world.